美国IgA肾病队列全身性糖皮质激素真实世界挑战数据表1

数据集获取（Figshare）

• 源站标题：Data Sheet 1_Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohort.pdf
• DOI：10.3389/fneph.2025.1574239.s001
• 发布日期：2025-04-24
• 文件数：1 个
• 文件总体积：278.10 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Real-world_challenges_associated_with_the_use_of_four_common_systemic_glucocorticoids_in_a_United_States_IgAN_cohort_pdf/28853192

命令行下载

curl -L -o "Data Sheet 1_Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohort.pdf" "https://ndownloader.figshare.com/files/53942627"

文件清单

• Data Sheet 1_Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohort.pdf（278.10 KB）

文件总体积 278.10 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

ObjectivesTo understand the difference in adverse events (AEs), healthcare resource utilization (HCRU), and kidney failure rates in immunoglobulin A nephropathy (IgAN) patients who initiated systemic glucocorticoid (SGC) treatment compared with those who did not.
MethodsThe overall cohort was selected from patients with IgAN (ICD-10 codes N02.8 and N04.1) identified in the TriNetX Dataworks database between January 2011 and May 2022. New initiators of dexamethasone, prednisone, prednisolone, or methylprednisolone (SGC cohort) were propensity score (PS) matched 1:1 with patients who did not receive SGC (non-SGC cohort) based on their characteristics at diagnosis. The index date was the date of SGC initiation; for the non-SGC cohort, a pseudo-index date was assigned using the same lag from diagnosis to index date as their PS-matched pairs. Patients with kidney failure before the index/pseudo-index date and their 1:1 PS-matched pairs were excluded.
ResultsThe final analysis was conducted in 802 patients (401 PS-matched pairs, mean age 41.2 years, 55% male). Median duration of follow-up was 3.5 and 3.1 years for the SGC and non-SGC cohorts, respectively. Compared with the non-SGC cohort, patients in the SGC cohort had greater frequency of several AEs, including severe infections, greater annualized HCRU and costs, and greater incidence of kidney failure.
ConclusionsThis study found that SGC therapy may increase adverse reactions and HCRU in IgAN patients, while comparatively providing no beneficial effects on preserving kidney function.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fneph.2025.1574239.s001（source: https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Real-world_challenges_associated_with_the_use_of_four_common_systemic_glucocorticoids_in_a_United_States_IgAN_cohort_pdf/28853192）。